Epstein-Barr virus latent membrane protein 1 peptide–Major Histocompatibility Complex (LMP1-pMHC)

The Epstein-Barr virus latent membrane protein 1 peptide–Major Histocompatibility Complex (LMP1-pMHC) is a specialized therapeutic target consisting of processed fragments of the LMP1 viral protein presented on the surface of infected cells by MHC class I molecules, most commonly HLA-A*02:01. LMP1 is a primary oncogene of the Epstein-Barr virus (EBV) that mimics CD40 signaling to promote cell survival and proliferation, playing a critical role in the development of EBV-associated malignancies such as nasopharyngeal carcinoma and various lymphomas. Because LMP1 is an intracellular or transmembrane protein with limited extracellular exposure in its native form, the pMHC complex serves as a vital 'window' for the immune system to identify and eliminate latently infected or cancerous cells. Therapeutic strategies targeting LMP1-pMHC include T-cell receptor-engineered T-cells (TCR-T) and TCR-like antibodies (or CAR-Ts derived from them) that can specifically bind the peptide-groove complex with high affinity. These approaches aim to bypass the immune evasion tactics of EBV-associated tumors, which often exhibit low levels of surface viral proteins but continue to present LMP1-derived peptides. Clinical development in this area focuses on achieving high specificity to avoid cross-reactivity with similar human self-peptides, which is a significant safety consideration for pMHC-targeted biologics.

Other names

LMP1-HLA complexEBV LMP1 peptide-MHC class I complexLMP1-HLA-A*02:01 complexEpstein-Barr virus latent membrane protein 1-MHC complex

T-cell receptor (TCR) mediated recognition and lysis, Antibody-dependent cellular cytotoxicity (ADCC), T-cell redirection